8-K Announcements
6Material company update
Apr 30, 2026·SEC
Material company update
Feb 3, 2026·SEC
Material company update
Dec 4, 2025·SEC
Merck & Co., Inc.(MRK)Earnings, Financials & Key Ratios
MRK•NYSE
15.6× P/E·Price updated Jun 19, 2026
AboutMerck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.Show more
- Revenue$64.93B+1.2%
- EBITDA$29.32B+18.6%
- Net Income$18.25B+6.6%
- EPS (Diluted)7.28+8.0%
- Gross Margin71.98%-5.7%
- EBITDA Margin45.17%+17.2%
- Operating Margin36.17%+14.8%
- Net Margin28.12%+5.4%
- ROE36.86%-9.5%
MRK Key Insights
Merck & Co., Inc. (MRK) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Excellent 3Y average ROE of 26.2%
- ✓Strong 5Y profit CAGR of 20.9%
- ✓FCF machine: 19.0% free cash flow margin
- ✓15 consecutive years of dividend growth
- ✓Healthy dividend yield of 2.9%
- ✓Healthy 5Y average net margin of 21.3%
✗Weaknesses
No significant weaknesses identified
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when MRK posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
MRK Price & Volume
Merck & Co., Inc. (MRK) stock price & volume — 10-year historical chart
Loading chart...
MRK Growth Metrics
Merck & Co., Inc. (MRK) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years5.1%
5 Years9.35%
3 Years3.08%
TTM1.18%
Profit CAGR
10 Years15.18%
5 Years20.9%
3 Years7.93%
TTM6.64%
EPS CAGR
10 Years16.65%
5 Years21.23%
3 Years8.43%
TTM8.17%
Return on Capital
10 Years14.28%
5 Years18.24%
3 Years17.07%
Last Year23.82%
MRK Recent Earnings
Merck & Co., Inc. (MRK) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 11/12 qtrs (92%)●Beat Revenue 11/12 qtrs (92%)
Q2 2026Latest
Apr 30, 2026Metric
Actual
Est
EPS
$1.28+12.9%
$1.47
Rev
$16.3B+2.8%
$15.8B
Q1 2026
Feb 3, 2026Metric
Actual
Est
EPS
$2.04+1.5%
$2.01
Rev
$16.4B+1.2%
$16.2B
Q4 2025
Oct 30, 2025Metric
Actual
Est
EPS
$2.58+9.3%
$2.36
Rev
$17.3B+1.8%
$17.0B
Q3 2025
Jul 29, 2025Metric
Actual
Est
EPS
$2.13+4.9%
$2.03
Rev
$15.8B-0.4%
$15.9B
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 30, 2026 | $1.28vs $1.47+12.9% | $16.3Bvs $15.8B+2.8% |
| Q1 2026 | Feb 3, 2026 | $2.04vs $2.01+1.5% | $16.4Bvs $16.2B+1.2% |
| Q4 2025 | Oct 30, 2025 | $2.58vs $2.36+9.3% | $17.3Bvs $17.0B+1.8% |
| Q3 2025 | Jul 29, 2025 | $2.13vs $2.03+4.9% | $15.8Bvs $15.9B-0.4% |
Based on last 12 quarters of dataView full earnings history →
MRK Peer Comparison
Merck & Co., Inc. (MRK) competitors in Vaccines and plasma-derived therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PFE | 143.46B | 25.22 | 18.54 | -1.65% | 11.83% | 8.34% | 0.78 | |
 LLY | 1.04T | 1098.13 | 47.85 | 44.7% | 34.98% | 101.17% | 1.60 | |
 ABBV | 383.17B | 216.63 | 91.41 | 8.57% | 6.91% | 62.15% | ||
 BMY | 110.25B | 54.00 | 15.65 | -0.22% | 15.01% | 38.96% | 2.55 | |
 AMGN | 182.2B | 337.60 | 23.72 | 9.92% | 20.95% | 89.41% | 6.31 | |
 JNJ | 550.4B | 228.39 | 39.45 | 4.3% | 27.26% | 31.69% | 0.51 | |
 AZN | 271.19B | 174.93 | 26.75 | 8.63% | 17.19% | 22.24% | 0.61 | |
 GSK | 101.9B | 50.67 | 6.86 | 4.11% | 19.19% | 31.48% | 1.11 |
Compare MRK vs Peers
Merck & Co., Inc. (MRK) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MRK Income Statement
Merck & Co., Inc. (MRK) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 40.12B | 42.29B | 39.12B | 41.52B | 48.7B | 59.28B | 60.12B | 64.17B | 64.93B |
Revenue Growth % | 0.79% | 5.41% | -7.5% | 6.13% | 17.31% | 21.72% | 1.4% | 6.74% | 1.18% |
Cost of Goods Sold | 12.91B | 13.51B | 12.02B | 13.62B | 13.63B | 17.41B | 16.13B | 15.19B | 18.2B |
COGS % of Revenue | 32.18% | 31.94% | 30.71% | 32.8% | 27.98% | 29.37% | 26.83% | 23.68% | 28.02% |
Gross Profit | 27.21B▲ 0% | 28.79B▲ 5.8% | 27.11B▼ 5.8% | 27.9B▲ 2.9% | 35.08B▲ 25.7% | 41.87B▲ 19.4% | 43.99B▲ 5.1% | 48.98B▲ 11.3% | 46.73B▼ 4.6% |
Gross Margin % | 67.82% | 68.06% | 69.28% | 67.2% | 72.02% | 70.63% | 73.17% | 76.32% | 71.98% |
Gross Profit Growth % | 5.56% | 5.79% | -5.84% | 2.93% | 25.73% | 19.37% | 5.06% | 11.33% | -4.58% |
Operating Expenses | 20.41B | 19.85B | 19.18B | 22.35B | 21.88B | 23.59B | 41.03B | 28.75B | 23.25B |
OpEx % of Revenue | 50.88% | 46.94% | 49.02% | 53.84% | 44.92% | 39.79% | 68.26% | 44.81% | 35.8% |
Selling, General & Admin | 10.07B | 10.1B | 9.46B | 8.57B | 9.4B | 9.67B | 9.88B | 10.1B | 10.73B |
SG&A % of Revenue | 25.11% | 23.89% | 24.17% | 20.64% | 19.31% | 16.31% | 16.44% | 15.74% | 16.53% |
Research & Development | 10.34B | 9.75B | 9.72B | 13.4B | 12.24B | 13.55B | 30.53B | 17.94B | 12.51B |
R&D % of Revenue | 25.77% | 23.06% | 24.86% | 32.27% | 25.14% | 22.85% | 50.79% | 27.95% | 19.27% |
Other Operating Expenses | 0 | 0 | 0 | 386M | 231M | 373M | 620M | 716M | 0 |
Operating Income | 6.8B▲ 0% | 8.93B▲ 31.4% | 7.93B▼ 11.3% | 5.55B▼ 30.0% | 13.2B▲ 137.9% | 18.28B▲ 38.5% | 2.95B▼ 83.8% | 20.22B▲ 584.5% | 23.49B▲ 16.1% |
Operating Margin % | 16.94% | 21.12% | 20.26% | 13.36% | 27.1% | 30.84% | 4.91% | 31.51% | 36.17% |
Operating Income Growth % | 23.6% | 31.4% | -11.25% | -30% | 137.91% | 38.51% | -83.84% | 584.53% | 16.15% |
EBITDA | 11.47B | 13.45B | 11.24B | 9.03B | 16.41B | 22.19B | 6.83B | 24.72B | 29.32B |
EBITDA Margin % | 28.6% | 31.8% | 28.72% | 21.76% | 33.7% | 37.43% | 11.35% | 38.52% | 45.17% |
EBITDA Growth % | 4.59% | 17.23% | -16.46% | -19.6% | 81.68% | 35.2% | -69.24% | 262.14% | 18.62% |
D&A (Non-Cash Add-back) | 4.68B | 4.52B | 3.31B | 3.49B | 3.21B | 3.91B | 3.87B | 4.5B | 5.84B |
EBIT | 7.28B | 9.47B | 12.36B | 6.69B | 14.69B | 17.41B | 3.04B | 21.21B | 23.49B |
Net Interest Income | -369M | -429M | -619M | -772M | -770M | -805M | -781M | -856M | -1.01B |
Interest Income | 385M | 343M | 274M | 59M | 36M | 157M | 365M | 415M | 343M |
Interest Expense | 754M | 772M | 893M | 831M | 806M | 962M | 1.15B | 1.27B | 1.36B |
Other Income/Expense | -276M | -230M | -755M | 315M | 680M | -1.84B | -1.06B | -285M | -2.42B |
Pretax Income | 6.52B▲ 0% | 8.7B▲ 33.4% | 7.17B▼ 17.6% | 5.86B▼ 18.2% | 13.88B▲ 136.7% | 16.44B▲ 18.5% | 1.89B▼ 88.5% | 19.94B▲ 955.4% | 21.07B▲ 5.7% |
Pretax Margin % | 16.25% | 20.57% | 18.33% | 14.12% | 28.5% | 27.74% | 3.14% | 31.07% | 32.45% |
Income Tax | 4.1B | 2.51B | 1.56B | 1.34B | 1.52B | 1.92B | 1.51B | 2.8B | 2.8B |
Effective Tax Rate % | 62.92% | 28.82% | 21.82% | 22.86% | 10.96% | 11.66% | 80.04% | 14.06% | 13.31% |
Net Income | 2.39B▲ 0% | 6.22B▲ 159.8% | 9.84B▲ 58.2% | 7.07B▼ 28.2% | 13.05B▲ 84.6% | 14.52B▲ 11.3% | 365M▼ 97.5% | 17.12B▲ 4589.6% | 18.25B▲ 6.6% |
Net Margin % | 5.97% | 14.71% | 25.16% | 17.02% | 26.79% | 24.49% | 0.61% | 26.68% | 28.12% |
Net Income Growth % | -38.93% | 159.82% | 58.25% | -28.2% | 84.65% | 11.27% | -97.49% | 4589.59% | 6.64% |
Net Income (Continuing) | 2.42B | 6.19B | 5.61B | 4.52B | 12.36B | 14.53B | 377M | 17.13B | 18.26B |
Discontinued Operations | 0 | 0 | 4.15B | 2.55B | 704M | 0 | 0 | 0 | 0 |
Minority Interest | 233M | 181M | 94M | 87M | 73M | 67M | 54M | 59M | 56M |
EPS (Diluted) | 0.93▲ 0% | 2.32▲ 149.5% | 3.82▲ 64.7% | 2.78▼ 27.2% | 5.14▲ 84.9% | 5.71▲ 11.1% | 0.14▼ 97.5% | 6.74▲ 4714.3% | 7.28▲ 8.0% |
EPS Growth % | -54.41% | 149.46% | 64.66% | -27.23% | 84.89% | 11.09% | -97.55% | 4714.29% | 8.01% |
EPS (Basic) | 0.95 | 2.40 | 3.84 | 2.79 | 5.16 | 5.73 | 0.14 | 6.76 | 7.30 |
Diluted Shares Outstanding | 2.75B | 2.68B | 2.58B | 2.54B | 2.54B | 2.54B | 2.55B | 2.54B | 2.51B |
Basic Shares Outstanding | 2.7B | 2.59B | 2.56B | 2.53B | 2.53B | 2.53B | 2.61B | 2.53B | 2.5B |
Dividend Payout Ratio | 215.83% | 83.15% | 57.86% | 87.94% | 50.66% | 48.3% | 2039.73% | 45.8% | 44.79% |
MRK Balance Sheet
Merck & Co., Inc. (MRK) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 24.77B | 25.88B | 27.48B | 27.76B | 30.27B | 35.72B | 32.17B | 38.78B | 43.52B |
Cash & Short-Term Investments | 8.5B | 8.86B | 10.45B | 8.05B | 8.1B | 13.19B | 7.09B | 13.69B | 14.56B |
Cash Only | 6.09B | 7.96B | 9.68B | 8.05B | 8.1B | 12.69B | 6.84B | 13.24B | 14.56B |
Short-Term Investments | 2.41B | 899M | 774M | 0 | 0 | 498M | 252M | 447M | 0 |
Accounts Receivable | 6.87B | 7.07B | 6.78B | 6.8B | 9.23B | 9.45B | 10.35B | 10.28B | 12.68B |
Days Sales Outstanding | 62.53 | 61.02 | 63.24 | 59.81 | 69.17 | 58.18 | 62.84 | 58.46 | 71.28 |
Inventory | 5.1B | 5.44B | 5.98B | 5.55B | 5.95B | 5.91B | 6.36B | 6.11B | 6.66B |
Days Inventory Outstanding | 144.06 | 146.98 | 181.59 | 148.86 | 159.46 | 123.92 | 143.91 | 146.76 | 133.56 |
Other Current Assets | 4.3B | 4.5B | 4.28B | 7.36B | 6.99B | 7.17B | 8.37B | 8.71B | 9.49B |
Total Non-Current Assets | 63.11B | 56.76B | 56.91B | 63.82B | 75.43B | 73.44B | 74.51B | 78.32B | 93.35B |
Property, Plant & Equipment | 12.44B | 13.29B | 15.05B | 17B | 19.28B | 21.42B | 23.05B | 23.78B | 26.82B |
Fixed Asset Turnover | 3.23x | 3.18x | 2.60x | 2.44x | 2.53x | 2.77x | 2.61x | 2.70x | 2.42x |
Goodwill | 18.28B | 18.25B | 19.43B | 18.88B | 21.26B | 21.2B | 21.2B | 21.67B | 21.58B |
Intangible Assets | 14.18B | 13.1B | 14.2B | 14.1B | 22.93B | 20.27B | 18.01B | 16.37B | 26.68B |
Long-Term Investments | 12.13B | 6.23B | 1.47B | 785M | 370M | 1.01B | 252M | 463M | 2.24B |
Other Non-Current Assets | 6.08B | 5.88B | 6.77B | 13.06B | 11.58B | 9.53B | 12B | 16.04B | 16.03B |
Total Assets | 87.87B▲ 0% | 82.64B▼ 6.0% | 84.4B▲ 2.1% | 91.59B▲ 8.5% | 105.69B▲ 15.4% | 109.16B▲ 3.3% | 106.67B▼ 2.3% | 117.11B▲ 9.8% | 136.87B▲ 16.9% |
Asset Turnover | 0.46x | 0.51x | 0.46x | 0.45x | 0.46x | 0.54x | 0.56x | 0.55x | 0.47x |
Asset Growth % | -7.87% | -5.96% | 2.13% | 8.52% | 15.4% | 3.28% | -2.28% | 9.78% | 16.87% |
Total Current Liabilities | 18.61B | 22.21B | 22.22B | 27.33B | 23.87B | 24.24B | 25.69B | 28.42B | 28.33B |
Accounts Payable | 3.1B | 3.32B | 3.74B | 4.33B | 4.61B | 4.26B | 3.92B | 4.08B | 4.4B |
Days Payables Outstanding | 87.69 | 89.65 | 113.55 | 115.98 | 123.46 | 89.39 | 88.77 | 97.99 | 88.35 |
Short-Term Debt | 3.06B | 5.31B | 3.61B | 6.43B | 2.41B | 1.95B | 1.37B | 2.65B | 2.88B |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 795M | -304M | -281M | -285M | -282M | 14.09B |
Current Ratio | 1.33x | 1.17x | 1.24x | 1.02x | 1.27x | 1.47x | 1.25x | 1.36x | 1.54x |
Quick Ratio | 1.06x | 0.92x | 0.97x | 0.81x | 1.02x | 1.23x | 1.00x | 1.15x | 1.30x |
Cash Conversion Cycle | 118.89 | 118.36 | 131.28 | 92.69 | 105.17 | 92.71 | 117.97 | 107.23 | 116.49 |
Total Non-Current Liabilities | 34.69B | 33.55B | 36.18B | 38.86B | 43.56B | 38.86B | 43.35B | 42.31B | 55.88B |
Long-Term Debt | 21.35B | 19.81B | 22.74B | 25.36B | 30.69B | 28.75B | 33.68B | 34.46B | 46.75B |
Capital Lease Obligations | 0 | 0 | 768M | 1.33B | 1.23B | 1.01B | 928M | 877M | 901M |
Deferred Tax Liabilities | 2.22B | 1.7B | 1.47B | 1B | 3.44B | 1.79B | 871M | 1.39B | 1.44B |
Other Non-Current Liabilities | 11.12B | 12.04B | 11.2B | 11.16B | 8.21B | 7.31B | 7.86B | 5.59B | 6.79B |
Total Liabilities | 53.3B | 55.76B | 58.4B | 66.18B | 67.44B | 63.1B | 69.04B | 70.73B | 84.2B |
Total Debt | 24.41B | 25.11B | 27.35B | 33.42B | 34.63B | 31.98B | 36.27B | 38.27B | 50.53B |
Net Debt | 18.32B | 17.15B | 17.68B | 25.37B | 26.54B | 19.29B | 29.43B | 25.03B | 35.97B |
Debt / Equity | 0.71x | 0.93x | 1.05x | 1.32x | 0.91x | 0.69x | 0.96x | 0.83x | 0.96x |
Debt / EBITDA | 2.13x | 1.87x | 2.43x | 3.70x | 2.11x | 1.44x | 5.31x | 1.55x | 1.72x |
Net Debt / EBITDA | 1.60x | 1.28x | 1.57x | 2.81x | 1.62x | 0.87x | 4.31x | 1.01x | 1.23x |
Interest Coverage | 9.65x | 12.27x | 13.84x | 8.06x | 18.22x | 18.09x | 2.65x | 16.69x | 17.31x |
Total Equity | 34.57B▲ 0% | 26.88B▼ 22.2% | 26B▼ 3.3% | 25.4B▼ 2.3% | 38.26B▲ 50.6% | 46.06B▲ 20.4% | 37.63B▼ 18.3% | 46.37B▲ 23.2% | 52.66B▲ 13.6% |
Equity Growth % | -14.24% | -22.24% | -3.28% | -2.3% | 50.59% | 20.39% | -18.29% | 23.22% | 13.56% |
Book Value per Share | 12.58 | 10.03 | 10.08 | 10.00 | 15.07 | 18.12 | 14.78 | 18.25 | 21.01 |
Total Shareholders' Equity | 34.34B | 26.7B | 25.91B | 25.32B | 38.18B | 45.99B | 37.58B | 46.31B | 52.61B |
Common Stock | 1.79B | 1.79B | 1.79B | 1.79B | 1.79B | 1.79B | 1.79B | 1.79B | 1.79B |
Retained Earnings | 41.35B | 42.58B | 46.6B | 47.36B | 53.7B | 61.08B | 53.9B | 63.07B | 73.08B |
Treasury Stock | -43.79B | -50.93B | -55.95B | -56.79B | -57.11B | -56.49B | -57.45B | -58.3B | -63B |
Accumulated OCI | -4.91B | -5.54B | -6.19B | -6.63B | -4.43B | -4.77B | -5.16B | -4.95B | -4.29B |
Minority Interest | 233M | 181M | 94M | 87M | 73M | 67M | 54M | 59M | 56M |
MRK Cash Flow Statement
Merck & Co., Inc. (MRK) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 6.45B | 10.92B | 13.44B | 10.25B | 14.11B | 19.09B | 13.01B | 21.47B | 16.47B |
Operating CF Margin % | 16.07% | 25.82% | 34.36% | 24.7% | 28.97% | 32.21% | 21.64% | 33.46% | 25.37% |
Operating CF Growth % | -37.87% | 69.41% | 23.05% | -23.71% | 37.61% | 35.34% | -31.89% | 65.06% | -23.27% |
Net Income | 2.42B | 6.19B | 9.78B | 7.08B | 12.36B | 14.53B | 365M | 17.13B | 18.25B |
Depreciation & Amortization | 4.64B | 4.52B | 3.65B | 3.63B | 3.21B | 3.91B | 3.87B | 4.5B | 5.84B |
Stock-Based Compensation | 312M | 348M | 417M | 441M | 479M | 541M | 645M | 761M | 0 |
Deferred Taxes | -2.62B | -509M | -556M | -668M | 187M | -1.57B | -1.9B | -1.25B | -1.67B |
Other Non-Cash Items | 6.72B | 1.92B | 2.22B | 4.36B | 1.71B | 4.47B | 12.23B | 3.99B | 1.03B |
Working Capital Changes | -5.02B | -1.55B | -2.07B | -4.59B | -3.84B | -2.78B | -2.21B | -3.67B | -6.98B |
Change in Receivables | 297M | -418M | 294M | -1B | -2.03B | -644M | -1.15B | -244M | -1.09B |
Change in Inventory | -145M | -911M | -508M | -855M | -674M | -161M | -816M | -835M | -1.18B |
Change in Payables | 254M | 230M | 399M | 724M | 405M | -289M | -380M | 182M | 110M |
Cash from Investing | 2.68B | 4.31B | -2.63B | -9.44B | -16.55B | -4.96B | -14.08B | -7.73B | -13.74B |
Capital Expenditures | -1.89B | -2.62B | -3.47B | -4.68B | -4.45B | -4.39B | -3.86B | -3.37B | -4.11B |
CapEx % of Revenue | 4.71% | 6.18% | 8.88% | 11.28% | 9.13% | 7.4% | 6.43% | 5.25% | 6.33% |
Acquisitions | -396M | -431M | -4.95B | -6.61B | -12.91B | -121M | -12.03B | -4.09B | -10.04B |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | 38M | 102M | 378M | 130M | -225M | 32M | 1.11B | -127M | -58M |
Cash from Financing | -10.01B | -13.16B | -8.86B | -2.83B | 2.59B | -9.12B | -4.81B | -7.03B | -1.92B |
Debt Issued (Net) | -1.13B | 837M | 1.25B | 5.01B | 1.63B | -2.25B | 4.18B | 2.31B | 11.38B |
Equity Issued (Net) | -4.01B | -9.09B | -4.78B | -1.28B | -840M | 384M | -1.35B | -1.31B | -4.99B |
Dividends Paid | -5.17B | -5.17B | -5.7B | -6.21B | -6.61B | -7.01B | -7.45B | -7.84B | -8.18B |
Share Repurchases | -4.01B | -9.09B | -4.78B | -1.28B | -840M | 0 | -1.35B | -1.31B | -5.08B |
Other Financing | 304M | 266M | 366M | -347M | 8.41B | -240M | -203M | -195M | -131M |
Net Change in Cash | -423M▲ 0% | 1.87B▲ 542.3% | 1.97B▲ 5.1% | -1.77B▼ 189.9% | 14M▲ 100.8% | 4.61B▲ 32800.0% | -5.86B▼ 227.3% | 6.41B▲ 209.3% | 1.37B▼ 78.6% |
Free Cash Flow | 4.56B▲ 0% | 8.31B▲ 82.1% | 9.97B▲ 20.0% | 5.82B▼ 41.6% | 9.66B▲ 65.9% | 14.71B▲ 52.2% | 9.14B▼ 37.8% | 18.1B▲ 97.9% | 12.36B▼ 31.7% |
FCF Margin % | 11.37% | 19.64% | 25.48% | 14.03% | 19.84% | 24.81% | 15.21% | 28.2% | 19.04% |
FCF Growth % | -47.92% | 82.05% | 19.98% | -41.57% | 65.88% | 52.23% | -37.83% | 97.92% | -31.7% |
FCF per Share | 1.66 | 3.10 | 3.86 | 2.29 | 3.81 | 5.79 | 3.59 | 7.12 | 4.93 |
FCF Conversion (FCF/Net Income) | 2.69x | 1.76x | 1.37x | 1.45x | 1.08x | 1.32x | 35.63x | 1.25x | 0.90x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
MRK Key Ratios
Merck & Co., Inc. (MRK) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 9.22% | 6.39% | 20.24% | 37.23% | 27.5% | 41% | 34.44% | 0.87% | 40.75% | 36.86% |
Return on Invested Capital (ROIC) | 6.8% | 9.14% | 13.82% | 13.56% | 8.81% | 17.13% | 21.07% | 3.35% | 21.91% | 22.01% |
Gross Margin | 64.75% | 67.82% | 68.06% | 69.28% | 67.2% | 72.02% | 70.63% | 73.17% | 76.32% | 71.98% |
Net Margin | 9.85% | 5.97% | 14.71% | 25.16% | 17.02% | 26.79% | 24.49% | 0.61% | 26.68% | 28.12% |
Debt / Equity | 0.62x | 0.71x | 0.93x | 1.05x | 1.32x | 0.91x | 0.69x | 0.96x | 0.83x | 0.96x |
Interest Coverage | 7.72x | 9.65x | 12.27x | 13.84x | 8.06x | 18.22x | 18.09x | 2.65x | 16.69x | 17.31x |
FCF Conversion | 2.65x | 2.69x | 1.76x | 1.37x | 1.45x | 1.08x | 1.32x | 35.63x | 1.25x | 0.90x |
Revenue Growth | 0.78% | 0.79% | 5.41% | -7.5% | 6.13% | 17.31% | 21.72% | 1.4% | 6.74% | 1.18% |
Related:MRK Dividend History·MRK Revenue History·MRK Price History·MRK P/E History·MRK Financial Ratios·MRK Institutional Holders
MRK SEC Filings & Documents
Merck & Co., Inc. (MRK) SEC filings — annual & quarterly reports (10-K, 10-Q)
MRK Frequently Asked Questions
Merck & Co., Inc. (MRK) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Merck & Co., Inc. (MRK) reported $64.93B in revenue for fiscal year 2025. This represents a 227% increase from $19.83B in 1996.
Merck & Co., Inc. (MRK) grew revenue by 1.2% over the past year. Growth has been modest.
Yes, Merck & Co., Inc. (MRK) is profitable, generating $18.25B in net income for fiscal year 2025 (28.1% net margin).
Dividend & Returns
Yes, Merck & Co., Inc. (MRK) pays a dividend with a yield of 2.86%. This makes it attractive for income-focused investors.
Merck & Co., Inc. (MRK) has a return on equity (ROE) of 36.9%. This is excellent, indicating efficient use of shareholder capital.
Merck & Co., Inc. (MRK) generated $12.36B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.